Drug Trial Radar · NCT05673811
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Jan 10, 2023
Primary completion
Mar 28, 2025
Study completion Mar 28, 2025
Sponsor
- Lead sponsor
- Theriva Biologics SLIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Conditions
- Pancreatic Adenocarcinoma
- Metastatic
Interventions
Nab-paclitaxelDrug
Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
GemcitabineDrug
Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
VCN-01Genetic
VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From date of randomization until the date of death from any cause, assessed up to 27 months
- Number of TEAEs in Each Treatment ArmTime frame: until the end of treatment period phase
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
University of California - Davis Cancer Center
Sacramento, California
University of Louisville - Brown Cancer Center
Louisville, Kentucky
Weill Cornell Medical Center
New York, New York
Martha Morehouse Tower
Columbus, Ohio
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah
Virginia Cancer Specialists
Fairfax, Virginia
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Duran i Reynals (ICO)
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Gregorio Marañon
Madrid, Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Málaga, Spain
Hospital General Univesitario de Valencia
Valencia, Valencia, Spain
Hospital Miguel Servet
Zaragoza, Zaragoza, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.